In contrast, 41.0% of SUN-treated patients in CheckMate 9ER, which compared NIVO + CABO with SUN, received subsequent anti-cancer therapy, of which 31.0% received PD-1 or PD-L1 inhibitor [31]. The gene discussed is CD274; the disease is cancer.